Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hospital push could shield seniors from preventable diseases

NCT ID NCT03587610

Prevention Sponsor: Centre Hospitalier le Mans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial evaluates whether a hospital-based remedial vaccination strategy can improve Tdap-IPV (tetanus, diphtheria, pertussis, polio) vaccination rates in adults aged 65 and older in the Sarthe region of France. Participants are randomly assigned to receive either the remedial strategy or standard care, and the study measures changes in immunization coverage. The goal is to find an effective way to protect older adults from these serious infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tdap-IPV vaccine (tetanus, diphtheria, pertussis, polio)
What this could lead to
If successful, this approach could help increase vaccination coverage among older adults, reducing the risk of preventable diseases in this age group.
What could go wrong
The study is small and focused on one region in France, so results may not apply elsewhere. It tests a process, not a new vaccine, so the impact depends on how well hospitals adopt the strategy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

218 people

The number who actually took part.

Started

May 2018

Finished

Mar 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 65 years or older * Patients capable of understanding and giving informed consent to participate in the study * Valid social security coverage Exclusion Criteria: * Patients under judicial safeguard measures * Refusal to participate in the study * Vaccination contra-indication * Patient already included in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vaccination are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diphtheria prevention target pertussis prevention target poliomyelitis prevention target tetanus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vaccination

Contacts and locations

Locations

  • Centre Hospitalier Le Mans

    Le Mans, 72 000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.